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Abstract 
M. genitalium is one of the major causes of non-gonococcal urethritis (NGU) worldwide but an 
uncommon sexually transmitted infection (STI) in the general population. The risk of sexual 
transmission is probably lower than for C. trachomatis. Infection in men is usually asymptomatic and 
it is likely most men resolve infection without developing disease. The incubation period for NGU 
caused by M. genitalium is probably longer than for NGU caused by C. trachomatis. The clinical 
characteristics of symptomatic NGU have not been shown to identify the pathogen specific 
aetiology. Effective treatment of men and their sexual partner(s) is complicated as macrolide 
antimicrobial resistance is now common in many countries, conceivably due to the widespread use 
of azithromycin 1g to treat STIs and the limited availability of diagnostic tests for M. genitalium. 
Improved outcomes in men with NGU and better antimicrobial stewardship are likely to arise from 
the introduction of diagnostic M. genitalium NAAT testing including antimicrobial resistance testing 
in men with symptoms of NGU as well as in their current sexual partner(s). The cost effectiveness of 
these approaches need further evaluation. The evidence that M. genitalium causes epididymo-
orchitis, proctitis, reactive arthritis and facilitates HIV transmission in men is weak, although 
biological plausible. In the absence of randomised controlled trials demonstrating cost effectiveness, 
screening asymptomatic men cannot be recommended. 
 
Introduction 
Mycoplasma genitalium is a sexually transmitted micro-organism which has the potential to cause 
clinical disease; in men more so than women. Although it was first identified in men with NGU in 
1980 much remains unclear about the natural history of untreated infection. While there is clear 
association with NGU in men the clinical evidence that it causes epididymo-orchitis, proctitis, 
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reactive arthritis and facilitates HIV transmission in men is weak, although biological plausible. It is 
not known how long asymptomatic infection persists in untreated men, nor the risk of developing 
disease if left untreated. Although there is evidence of sexual transmission from male to female, it is 
unclear how often this occurs and of the risk of developing reproductive tract disease.  
With the advent of commercially available tests in some countries but not the United States, M. 
genitalium diagnosis  is now possible in some settings. However, the cost effectiveness of screening  
and diagnostic testing using M. genitalium NAAT testing has not been evaluated in randomised trials. 
Undertaking and interpreting such clinical studies will be complex as macrolide antimicrobial 
resistance is now common in many countries most likely due to the widespread use of azithromycin 
1 g to treat STIs  and flouroquinolone resistance is beginning to emerge.[1-4]  This emphasises the 
importance of adopting the principles of good antimicrobial stewardship, including the use of 
accurate diagnostics (https://www.nice.org.uk/guidance/ng15/chapter/1-Recommendations#terms-
used-in-this-guideline) and undertaking a test of cure, when considering how best to manage this 
infection in clinical practice.[2]  
In this review article the evidence available on the epidemiology, clinical presentation and natural 
history in men is examined.   The review article also examines the potential benefits of utilising M. 
genitalium NAAT testing in a diagnostic setting with and without antimicrobial resistance testing not 
only in managing the patient but its potential role in informing partner notification and treatment.  
 
Epidemiology 
There are two large population based survey studies of M. genitalium available that have provided 
us with unbiased information on the epidemiology of this emerging sexually transmitted pathogen in 
asymptomatic men.[5, 6] The first of these was based on Wave III of the National Longitudinal Study 
of Adolescent Health in the USA. Young adults between the ages of 18 and 27 years were enrolled 
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between 2001-2002. M genitalium prevalence in men was 1.1% and 0.8% in women, with an overall 
prevalence of 1.0%. In contrast the prevalences of chlamydial, gonococcal and trichomonal 
infections were 4.2%, 0.4% and 2.3% respectively.  After adjustment for other risk factors M. 
genitalium infection was strongly associated with increasing numbers of sexual partners and black 
race. The second study was a probability sample survey in Britain: The National Survey of Sexual 
Attitudes and Lifestyles (NATSAL-3) conducted between 2010 and 2012 among sexually experienced 
men and women between the ages of 16 and 44. In this study, the prevalence of M. genitalium in 
men was 1.2% and in 1.3% in women. Risk factors for M. genitalium infection included black race, 
increased numbers of total and new sex partners, and unsafe sexual practices. A smaller population 
based survey of young men aged 21-24yrs  from Aarhus County, in  Denmark 1997-98 observed a 
similar prevalence  of 1.1% and an association with increasing number of sexual partners.[7] 
Among males the most common clinical manifestation of M. genitalium infection is NGU. It is 
currently unknown what proportion of men infected with M. genitalium develop NGU but is 
probably only a minority. If we assume a duration of infection of 1 year we can estimate using data 
from England in 2011 that approximately 6500 (5.2%) of 125,000 men M. genitalium-positive men 
developed NGU. [8-12] Totten and McGowin in this supplement review mechanisms of persistence 
and immune evasion by M. genitalium which enable it  to establish chronic and persistent 
infection.[13] Women can resolve infection spontaneously and it is likely men can as well. The 
duration of infection in women varies from a few months to over a year however we do not know 
the duration of infection in men.[14-17]  
The proportion of cases caused by M. genitalium varies geographically and by socio economic status. 
Neisseria gonorrhoeae is the most common cause of urethritis in most developing regions of the 
world.[18] Chlamydia trachomatis is the most common pathogen associated with NGU followed by 
M. genitalium and in the USA Trichomonas vaginalis.[19-21] M. genitalium can also cause infection 
in  men with gonococcal urethritis though,  C. trachomatis is more common.[18, 22] M. genitalium is 
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now recognized as the dominant organism associated with persistent NGU following treatment of 
NGU.[19]  
Survey studies of men-who-have-sex-with-men (MSM) reveal higher rates of all STIs than observed 
in population based surveys. In a survey of MSM attending sauna’s in Australia, Bradshaw et. al.[23] 
found the prevalence of M. genitalium to be 2.1% compared to prevalence rates of 8.1% for C. 
trachomatis and 4.8% for N. gonorrhoeae.  Importantly, all organisms were significantly more 
common in the rectum than in either the urethra or the pharynx. These findings have been 
replicated in several other studies of different MSM populations.[24-26]  Of interest, C. trachomatis 
and M. genitalium prevalence rates are lower among MSM with NGU than  in heterosexual men with  
a higher proportion of NGU cases are idiopathic in MSM.[27,28]  Soni et. al.[24]  found that M. 
genitalium was more prevalent in men with HIV infection while the prevalence of C. trachomatis and 
N. gonorrhoeae was not influenced by HIV status. If supported this finding may provide clues to key 
differences in the host immune response to these organisms.  
In summary, M. genitalium is one of the major causes of NGU worldwide but an uncommon sexually 
transmitted infection (STI) in the general population. Infection in men is usually asymptomatic and it 
is likely most men resolve infection without developing disease. 
 
Immunopathogenesis: NGU and proctitis  
M. genitalium is a slow growing micro-organism which can replicate both intracellularly and 
extracellularly and is able to establish chronic infections. [29] During chronic epithelial cell infection 
it  produces pro-inflammatory cytokines which predominantly consist of potent chemotactic and/or 
activating factors for phagocytes.[30] This is discussed in more detail by Totten and McGowin in this 
supplement.[13]  
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Sexual transmission 
Although it is now well established that M. genitalium is sexually transmitted it is not known how 
often this occurs per episode of unprotected sexual intercourse.[29] Estimates for chlamydial 
transmission from men to women per episode of vaginal coitus have been based on observational 
studies and range from 10% to 39.5% with the lower estimate based on a recent transmission 
dynamic mathematical model using the dyad study of Quinn et al.[31-33] Studies of sexual dyads 
suggest that transmission is probably lower than that for C. trachomatis which would be consistent 
with lower infectious load of M. genitalium compared to C. trachomatis.[33-35] It is likely that men 
with symptomatic NGU and presumably higher M. genitalium loads may be more infectious than 
men with asymptomatic infection. [34, 36-38]   Studies of both C. trachomatis and M. genitalium in 
older men also provide additional insights into the relative transmission dynamics of these 
commonly associated STIs.  Napierala et al.[39]  tested for M. genitalium in 2,750 preserved 
specimens originally submitted to a reference laboratory for C. trachomatis testing from STI and 
community clinics including men ranging in age from adolescents to those greater than 60 years of 
age. As has been shown in numerous STI clinic based studies, the highest prevalence of C. 
trachomatis infection was in the <20 age group with a progressive prevalence decrease to very low 
levels among individuals greater than 40 years of age. In contrast the age group with the highest 
prevalence of M. genitalium was in the 20 to 30-year-old age group. Though M. genitalium 
prevalence rates decreased in the above 30 age groups the decline was not as steep as was observed 
for C. trachomatis and, strikingly, among men >40, M. genitalium was more common than C. 
trachomatis. These findings were corroborated by the NATSAL-3 population based survey.[5, 40] 
Taken together these observations suggest the hypothesis that the average duration of M. 
genitalium infection in men is longer than the average duration of C. trachomatis infection while the 
lower prevalence of M. genitalium infection in younger males compared to C. trachomatis provides 
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further support for the hypothesis that infectivity of M. genitalium is lower than that of C. 
trachomatis.  
As carriage of M. genitalium in the oro-pharynx appears to be very uncommon, transmission through 
oral sex is likely to be rare.[41, 42] It is unknown whether risk of transmission differs between anal 
and vaginal intercourse.  
 
Mycoplasma genitalium and NGU 
Given that M. genitalium was first identified in men with NGU and that it induces the release of pro-
inflammatory cytokines  it is not surprising that M. genitalium has been strongly and consistently 
associated with NGU.[29, 30] Taylor-Robinson and Jensen in 2011 reviewed all the published 
literature and observed that M. genitalium has been detected in  15 to 25% of men with 
symptomatic NGU, compared to about 5 to 10% of those without disease (OR 5.5 (95% CI:4.3-
7.0))[29].  In several studies, the clinical characteristics of symptomatic NGU have not been shown to 
identify the pathogen specific aetiology. [20, 21, 43]   
 
Incubation period of NGU 
The recommended period for contact tracing in men presenting with NGU ranges from  4 weeks to 
60 days from the onset of symptoms. [19, 44] For the European guideline this is based on the 
assumption that the incubation period for chlamydial NGU is 2-4 weeks. Although the incubation 
period for the development of M. genitalium NGU is unknown, it is likely that M. genitalium’s slow 
replication rate compared to chlamydia would result in a more prolonged incubation period before 
NGU develops.[29] Thus, while, the limited evidence available suggests this  could be up to 60 days, 
it may be  potentially even longer.[30] Comparison of infectious disease epidemiology in men with  
chlamydia and M. genitalium  in NGU studies may provide insights as to whether this is the case. 
However, there are a number of biases which make these data  difficult to interpret including high 
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risk behaviour of controls and attendance as a result of being a contact of an STI.[9, 20] 
Nevertheless, in the case control study by Leung et al. men with M. genitalium NGU were no more 
likely to have had a new partner or more than one partner compared to controls whereas chlamydial 
NGU was associated with these behavioural risk factors.[9] Wetmore et al. observed that the mean 
duration of relationship for the most recent partner for men with NGU was longer for M. genitalium-
positive men (mean – 75 days) than for chlamydia-positive men (mean - 16 days). [21] These data 
provide additional support for the hypothesis that the infectivity of M. genitalium is less than that of 
C. trachomatis.  
 
 
Definition of NGU and initiating treatment 
There are two working definitions of NGU used in clinical practice.[19, 44] While both include the 
presence of urethral discharge, dysuria and/or urethral irritation  and the requirement for objective 
evidence of urethral inflammation, the European guideline uses > 5 PMNLs /high power field (x1000) 
(PMNLs/hpf) on a stained urethral smear and the U.S. CDC guideline uses > 2 PMNLs/hpf.[19, 44]    
Treatment using a lower cut-off may  result in over treatment of many men with low grade urethritis 
(2-4 PMNLs/hpf) who do not have an infection (see below).  In Europe it is recommended that 
symptomatic men with <5 PMNLs/hpf are reassured and asked to return for an early morning smear 
if their symptoms do not settle and their NAAT tests for C. trachomatis and N. gonorrhoeae are 
negative.[19]  This is because some men with low grade urethritis will have been misclassified 
because of the inaccuracy of the urethral smear .[8] There is currently no evidence of significant 
morbidity in symptomatic chlamydia and gonorrhoea NAAT-negative men with <5 PMNLs/hpf on a 
urethral smear who are reassured and do not receive anti-microbial therapy. Many of these men get 
better without treatment. [19]  
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While reducing the PMNL count cut-off will increase the number of men identified and treated for 
presumptive  chlamydia or  M. genitalium infection it will also disproportionately increase the 
number of men (and their partner(s)) without a sexually transmitted infection, diagnosed and 
treated for NGU. Figure 1 is a theoretical representation of the distribution of urinary leucocytes 
(ULs) of high risk men infected with M. genitalium. This representation is based on the findings of 
Wiggins et al who investigated the UL distribution in 87 high risk men presenting to a GUM 
department.[45] These men were tested for C. trachomatis, N. gonorrhoeae and urethritis but not  
M. genitalium. A previous study in the same population had demonstrated that M. genitalium 
prevalence was  about half that of C. trachomatis  and the observations of Moi et al indicate that the 
inflammatory response is less marked.[9, 46]  As the UL count and the PMNLs/hpf are correlated, 
changes in the UL count can be used to explore how changes in the urethral smear cut-off will effect 
detection of C. trachomatis, N. gonorrhoeae and M. genitalium. [45,46 When the UL threshold (see 
figure, threshold A), which approximated the urethral smear cut-off 5pmns/hpf in the study is 
lowered (see figure - threshold B) more high risk men in the population tested for urethritis with M. 
genitalium, C. trachomatis and N. gonorrhoeae will be identified. However, the specificity of 
urethritis for detecting men with these infections will also decrease and, as the cell count threshold 
is reduced, disproportionately more high risk men (and their partners) with no infection compared 
to those with an infection will require treatment as a result of being diagnosed with NGU. This would 
also be expected to be the case with a urethral smear. [45-47] While other infections such as 
Ureaplasma urealyticum or Trichomonas vaginalis (in populations where this micro-organism is 
prevalent) can account for some cases, the specific aetiology in men not infected with STI pathogens 
is unclear.[19] This concept is also consistent with the observations that idiopathic NGU has a lower 
mean leucocyte count compared to men in whom an infection is detected.[20, 21, 43]  
In summary, reducing the PMNL count cut-off from > 5 to > 2 to for diagnosing NGU will increase the 
number of men identified and treated for presumptive  chlamydia or  M. genitalium infection but 
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will also disproportionately increase the number of men (and their partner(s)) without a sexually 
transmitted infection, diagnosed and treated for NGU. 
 
NAAT testing for M. genitalium in men with symptoms of NGU 
Currently, NAAT testing is not available in many centres but anticipated over the next few years. The 
European NGU guideline advises that M. genitalium NAAT testing, preferably with macrolide 
resistance testing in men with NGU is likely to be cost effective, as this would enable the 
implementation of more effective treatment strategies. It is also likely that testing symptomatic 
men, who do not meet the PMNL NGU diagnosis criteria, for STI pathogens including M. genitalium 
and withholding treatment pending the results would reduce unnecessary antimicrobial therapy. 
Whether or not testing STI pathogen-NAAT negative, in this group of men, would reduce re-
attendance for an early morning smear and/or the persistence of symptoms, as currently 
recommended in Europe, remains to be demonstrated. (see Table) 
 
Retesting men if M. genitalium NAAT-positive 
The European guideline recommends that all persons testing M. genitalium NAAT-positive should be 
retested at the earliest 3 weeks after commencement of therapy due to the high prevalence of 
macrolide resistance either present pre-treatment or developing during treatment with 
azithromycin.[2] Many patients enter a stage of few or no symptoms after treatment, but with 
persistent carriage and subsequent risk for spread of resistance in the community.[2] 
 
 
Antimicrobial therapy for acute NGU  
The European  2016 NGU treatment guideline recommends that azithromycin 1g not be used as first 
line therapy, due to the accumulating evidence that this regimen  promotes macrolide antimicrobial 
resistance in M. genitalium and is only 87% effective in eradicating macrolide sensitive infection.[1, 
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4, 19] This is contrary to the 2015 CDC STD Treatment Guidelines and United Kingdom 2015 NGU 
treatment guidelines which recommend azithromycin 1 g for NGU.[44, 48]  These differences in 
treatment approach reflects how rapidly the evidence base concerning treatment of M. genitalium is 
changing. Given the new evidence and the imperative of good antimicrobial stewardship the 
continued recommendation of azithromycin 1g as first line treatment for NGU in the USA and the UK 
should be reviewed. [44, 48, 49] There is some evidence that in macrolide sensitive infection 
azithromycin 500mgs followed by  250mgs for 4 days may be  more effective and less likely to 
promote macrolide antimicrobial resistance, particularly if prescribed after a 7 day course of 
doxycycline. [19, 50-52] However a recent retrospective study from Australia suggests that the 
extended azithromycin regimen may not be more effective than 1g and also may be associated with 
promotion of macrolide antimicrobial resistance.[4, 53] It is unclear why the observations differ and 
may reflect differences in the populations studied with the latter including high risk men who have 
sex with men in whom three quarters of pre-treatment M. genitalium strains are macrolide 
resistant.[53]  
The European guideline recommends doxycycline 100mgs bid for 7 days as first line therapy for 
NGU.[19]  It is effective against chlamydia and, although it has markedly reduced efficacy against M. 
genitalium in treatment of wild-type infection compared to azithromycin 1g, it does not appear to 
promote tetracycline resistance. It also has the potential  benefit of reducing bacterial load which 
would theoretically reduce the risk of selection for both macrolide and quinolone resistance as a 
result of heterotypic resistance if these antimicrobials are subsequently prescribed in men who fail 
therapy.[54, 55] This is supported by the observational data from Anagrius et al. and Gesink et al. in 
which no macrolide antimicrobial resistance developed with the extended azithromycin after pre-
treatment  with doxycycline.[50, 52] Doxycycline efficacy also would not be affected by the presence 
of macrolide resistance, thus some macrolide resistant infections will also be eradicated.  
In summary, the recommendation of Azithromycin 1 g as first line treatment for NGU by the USA and 
the UK should be reviewed. Given the recent conflicting evidence on the efficacy of the extended 5 
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day regimen as first line therapy, it may be that Doxycycline 100mgs bd for 7 days is the most logical 
choice for use as first line therapy.  
 
New investigational antimicrobials and combination therapy 
Increasing rates of M. genitalium treatment failure due to antimicrobial resistance have resulted in 
an urgent need for new therapies which Bradshaw et al discuss in detail elsewhere in this 
supplement.[4]  
 
 
Management of persistent or recurrent NGU following initial treatment 
In 15-25% of men, persistent or recurrent symptoms can occur. While M. genitalium is an important 
cause, other aetiologies such as Trichomonas vaginalis need to be considered. The management of 
persistent or recurrent NGU can be challenging particularly in the absence of diagnostic testing for 
M. genitalium.[19]  In men initially treated with doxycycline, the extended 5 day azithromycin 
regimen is recommended by the European Guidelines. [19] The 2015 CDC STD Treatment guidelines 
recommend azithromycin 1g if the patient was initially treated with doxycycline which given the 
recent change in the evidence base should be reviewed.[44, 49]  If azithromycin had been used as 
first line therapy, then moxifloxacin 400mgs daily for 7-14 days is recommended [19, 44] although 
quinolone antimicrobial resistance is also beginning to emerge.[2, 4] A possible alternative approach 
in treatment failures initially treated with azithromycin, although not recommended in either the 
European or CDC Treatment Guidelines is the use of doxycycline as second line therapy. Doxycycline 
is 30-40% effective in eradicating M. genitalium irrespective of whether or not it is macrolide and/or 
quinolone resistant.[2, 4]Moreover, doxycycline is significantly cheaper than moxifloxacin and may 
be safer.  
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In Europe the concurrent administration of metronidazole is recommended in all men with NGU who 
fail 1st line therapy, whereas in the United States this is only recommended in men who have sex 
with women where Trichomonas vaginalis is prevalent.[19, 44]  
In summary, the management of persistent and recurrent NGU is challenging in the absence of M. 
genitalium NAAT and antimicrobial resistance testing. 
 
Partner notification and management 
Men with NGU. 
The primary aims of partner notification and treatment are to prevent re-infection of the index male, 
prevent complications of the infection in the partner(s) and reduce onward transmission. All current 
partner(s) should be tested and treated with the same treatment as the index patient and advised 
not to be sexually active until all have completed treatment and symptoms have resolved.[2, 19] This 
should be undertaken sensitively considering socio-cultural issues and avoiding stigma.[19] This is a 
complex issue given the limited availability of M. genitalium NAATs, the poor efficacy of current first-
line treatment regimens, the prevalence of M. genitalium macrolide resistance globally, and the 
observation that not all sexual partners are infected. The issue is even more complicated for other 
non-current partners in the three months prior to the index male’s diagnosis. Table 1 details the 
advantages of M. genitalium NAAT testing with or without antimicrobial resistance (AMR) testing in 
managing partners of men presenting with symptoms of NGU. In the United States there is no 
diagnostic test for M. genitalium that is cleared by the FDA for commercial use.  
In summary, current sexual partners should be tested and treated with the same treatment as the 
index patient. 
 
Persistent and recurrent NGU 
It is currently recommended that all recent sexual partner(s) (see above) should be tested for 
chlamydia and gonorrhoea using a NAAT and offered treatment.[19, 44] In men with persistent NGU, 
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in whom M. genitalium is common, in the absence of specific M. genitalium diagnostic testing it is 
unclear whether the partner should be retreated. It is likely that re-treatment of the sexual partner 
with the same antimicrobial therapy effective in the index case will be beneficial if 
persistent/recurrent NGU in the index case resolves following extended therapy, but subsequently 
recurs following sexual intercourse.[19]  
 
Other clinical syndromes potentially associated with M. genitalium 
Proctitis  
Proctitis is characterized clinically as rectal pain and/or rectal discharge. There is  one large study 
that demonstrates the association of M. genitalium with proctitis. Among 154 Australian MSM with 
proctitis Bissessor et al [56] reported a  M. genitalium prevalence of 12%,  N. gonorrhoeae – 25%, 
chlamydia– 19% and herpes simplex virus – 18%. M. genitalium was the only bacterial infection 
significantly associated with HIV infection in this study. Soni et al made the same observation in a 
survey of asymptomatic rectal carriage of STI pathogens. [24] Bissessor et al [56]  also found that the 
rectal M. genitalium bacterial load was significantly higher in men with proctitis compared to 
asymptomatic men. This finding parallels the results of quantitative studies of M. genitalium in 
urethral infections, however treatment outcomes were not evaluated.  There are no specific studies 
that have evaluated treatment effectiveness for M. genitalium proctitis.  
 
Prostatitis 
There is some data on the association of M. genitalium and prostatitis. Krieger et al. [557] reported 
that biopsies from 4% of 135 men with chronic prostatitis were positive by PCR for M. genitalium. 
Mo et al [58] recently described evaluation of 235 Chinese men with prostatitis and 152 
asymptomatic STI clinic controls who underwent the same specimen collection procedures including 
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prostate massage. Using a quantitative M. genitalium PCR assay 10% of men with clinical prostatitis 
had evidence of M. genitalium infection of the prostate based on detection of the organism only in 
expressed prostatic secretions and/or the post prostatic massage urine specimen or 4 fold higher M. 
genitalium DNA concentrations in these specimens relative to concentrations in first or mid-stream 
urine specimens. Only 3% of controls had evidence of M. genitalium in the prostate (P = 0.005). 
These data suggest that M genitalium can be a cause of prostatitis in a small proportion of cases but 
this requires confirmation. 
 
Epididymitis 
Given the parallels between clinical syndromes caused by C. trachomatis and M. genitalium it would 
be expected that  M. genitalium may result in epididymitis would result from infection. Hamasuna 
[59] described a patient with classic epididymitis from whom M. genitalium was the only known 
pathogen identified. There was no clinical response to minocycline and cephalosporin antibiotics but 
improvement was noted following the administration of levofloxacin.  Ito et al [60] recently reported 
on 56 cases of epididymitis in men less than 40 years old. C. trachomatis was associated with 50% of 
the cases while M. genitalium was present in  8%. Although there is limited data,  M. genitalium may 
cause epididymitis though  less commonly than C. trachomatis.   
 
Syndromes possibly associated with M. genitalium 
Given the association of C. trachomatis with post infectious arthritis, there is a possibility that  M. 
genitalium would be associated with this or other syndromes involving joint inflammation. [61, 62] 
Although Horner et al had reported that M. genitalium is associated with balano-posthitis such an 
association was not observed in the recent study by Ito et al.[43, 63]  
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HIV transmission 
M. genitalium infection is associated with HIV acquisition in women [64] which may be due to its 
ability to induce a pro-inflammatory response. Genital tract infections can  cause an inflammatory 
discharge which has been  associated with increased HIV shedding.[65]  Whether M. genitalium 
infected men practising unprotected anal intercourse may be more likely to be at an increased risk 
of HIV acquisition and, if HIV infected, more likely to transmit HIV during unprotected anal and 
insertive oral intercourse is as yet unknown. The inflammatory response associated with M. 
genitalium infection in men is less marked than that observed with chlamydia and gonorrhoea and 
one small study of men with NGNCU (M. genitalium was not tested for) did not demonstrate an 
increase in HIV load in the semen compared to controls. [66] 
 
Screening for M. genitalium in men 
In the absence of randomised controlled trials demonstrating cost effectiveness, screening 
asymptomatic men cannot be recommended. 
 
 
Conclusion 
M. genitalium is one of the major causes of NGU worldwide but an  uncommon sexually transmitted 
infection in the general population. Effective treatment is complicated as macrolide antimicrobial 
resistance is now common in many countries, conceivably as a result of widespread use of 
azithromycin 1g to treat STIs, and the limited availability of diagnostic tests for M. genitalium. 
Improved outcomes in men with NGU and better antimicrobial stewardship are likely to arise from 
introduction of diagnostic M. genitalium NAAT testing including antimicrobial resistance testing in 
men with symptoms of NGU as well as in their current sexual partner(s).  The cost effectiveness of 
these approaches need further evaluation.  
 18 
 
 
 
Figure 1 Hypothetical frequency distribution of urinary leucocyte counts for M. genitalium* and no 
infection* in high risk men presenting to a department of GUM who were tested for C. trachomatis 
and N. gonorrhoeae. Line A correlates with the urethral smear cut-off of 5 PMNLs /hpf for NGU and 
line B demonstrates the effect on sexually transmitted infection detection if the cut-off is decreased. 
Adapted from Wiggins et al.[45]  
 
 
 
 
 
  
 19 
 
    No M. genitalium NAAT 
testing following European 
guidelines 
No M. genitalium NAAT 
testing  following CDC 
guidelines 
M. genitalium NAAT testing plus 
knowledge of local  AMR1 
prevalence  
M. genitalium NAAT testing 
plus macrolide AMR testing 
and knowledge of local  
quinolone AMR prevalence  
M. genitalium NAAT testing plus 
macrolide and quinolone  AMR 
testing  
Symptoms of 
NGU 
Management NAAT test for CT2 and NG3 
and confirm patient has NGU 
based on > 5 PMNLs/hpf 
NAAT test for CT and NG and 
confirm patient has NGU 
based on > 2 PMNLs/hpf 
Confirm man has NGU on 
microscopy4 
Confirm man has NGU on 
microscopy4 
Confirm man has NGU on 
microscopy4 
Advantages / 
disadvantages  
Unable to reassure if low 
grade urethritis <5 
PMNLs/hpf5 
More CT infected men are 
treated but 
disproportionately greater 
increase in treatment of men 
with no infection (Figure 1)   
Able to reassure if low grade 
urethritis <5 PMNLs/hpf6 
Able to reassure if low grade 
urethritis <5 PMNLs/hpf6 
Able to reassure if low grade 
urethritis <5 PMNLs/hpf6 
Confirmed 
NGU  
Management  Doxycycline 100mgs bd 7 
days 
Azithromycin 1 g or 
Doxycycline 100mgs bd 7 
days 
Doxycycline 100mgs bd 7 days 
(European guideline) 
Doxycycline 100mgs bd 7 days 
(European guideline) 
Doxycycline 100mgs bd 7 days 
(European guideline) 
Advantages / 
disadvantages  
Does not reduce antimicrobial 
therapeutic options if 
treatment is not effective 
Azithromycin 1 g associated 
with  development of 
macrolide AMR in M. 
genitalium 
Does not reduce antimicrobial 
therapeutic options if treatment 
is not effective 
Does not reduce antimicrobial 
therapeutic options if 
treatment is not effective 
Does not reduce antimicrobial 
therapeutic options if treatment is 
not effective 
Contacts of 
NGU 
Management NAAT test for CT and NG then 
Doxycycline 100mgs bd 7 days 
Azithromycin 1 g or 
Doxycycline 100mgs bd 7 
Doxycycline 100mgs bd 7 days 
and test for M. genitalium4 
Doxycycline 100mgs bd 7 days 
and test for M. genitalium4 
Doxycycline 100mgs bd 7 days and 
test for M. genitalium4 
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days 
Advantages / 
disadvantages  
Does not reduce antimicrobial 
therapeutic options if 
treatment is not effective 
Azithromycin 1 g associated 
with development of 
macrolide AMR in M. 
genitalium 
Does not reduce antimicrobial 
therapeutic options if treatment 
is not effective 
Does not reduce antimicrobial 
therapeutic options if 
treatment is not effective 
Does not reduce antimicrobial 
therapeutic options if treatment is 
not effective 
Persistent/ 
recurrent 
NGU 
Management Azithromycin 5 day regimen7 
plus metronidazole 400mgs 
bd 5 days 
Moxifloxacin 400mgs of 7 
days if treated with 
azithromycin  1 g initially; 
Azithromycin 1 g if initial 
treatment doxycycline 
100mgs bd 7 days. Plus 
metronodazole/ Tinidazole 2g 
if partner(s) female and T.  
vaginalis prevalent 
Azithromycin 5 day regimen7 if 
M. genitalium negative. If M. 
genitalium  positive choice of 
azithromycin or moxifloxacin to 
be guided by local prevalence of 
macrolide and quinolone AMR. 
Plus metronidazole8 
Azithromycin 5 day regimen7  if 
M. genitalium negative. If M. 
genitalium positive choice of 
azithromycin or moxifloxacin to 
be guided by macrolide AMR 
result and knowledge of  local 
prevalence of quinolone AMR. 
Plus metronidazole8 
Azithromycin 5 day regimen7  if M. 
genitalium negative. If M. genitalium 
positive, choice of azithromycin or 
moxifloxacin to be guided by 
macrolide and quinolone AMR result. 
Plus metronidazole8 
Advantages / 
disadvantages  
Likely to be effective unless 
macrolide resistant M. 
genitalium aetiology of NGU 
Moxifloxacin effective against 
macrolide AMR M. 
genitalium.  Azithromycin 1 g 
associated with development 
of macrolide AMR in M. 
genitalium 
Improved cure rates following 
second line therapy 
Improved cure rates following 
second line therapy 
Improved cure rates following 
second line therapy 
M. Management Test of cure:  Not possible Test of cure:  Not possible Test of cure >  3 weeks after start Test of cure >  3 weeks after Test of cure >  3 weeks after start of 
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genitalium 
detected 
of treatment  start of treatment  treatment  
Advantages / 
disadvantages  
Risk of spread of resistant 
strains which have developed 
following treatment 
Risk of spread of resistant 
strains which have developed 
following treatment 
Prevents spread of resistant 
strains which have developed 
following treatment but are 
asymptomatic 
Prevents spread of resistant 
strains which have developed 
following treatment but are 
asymptomatic 
Prevents spread of resistant strains 
which have developed following 
treatment but are asymptomatic 
Contacts of 
persistent/ 
recurrent 
NGU 
Management No further treatment No further treatment Treatment guided by NAAT 
results of tests prior to  
epidemiological treatment 
Treatment guided by NAAT 
results of tests prior to  
epidemiological treatment 
Treatment guided by NAAT results of 
tests prior to  epidemiological 
treatment 
Advantages / 
disadvantages  
At risk of re-infection if M. 
genitalium aetiology of NGU 
At risk of re-infection if M. 
genitalium aetiology of NGU 
Reduced risk of re-infection and 
inappropriate additional 
antimicrobial therapy 
Reduced risk of re-infection 
and inappropriate additional 
antimicrobial therapy 
Reduced risk of re-infection and 
inappropriate additional 
antimicrobial therapy 
Antimicrobial 
stewardship 
  not good poor good very good very good 
1Antimicrobial resistance;  2 Chlamydia trachomatis; 3 Neisseria gonorrhoeae; 4 Assumes NAAT testing for Chlamydia, gonorrhoea which would also include trichomonas 
depending on local population prevalence; 5 Men are invited back for an early morning smear after holding their urine over night if symptoms do not settle and CT and 
NG NAAT-negative; 6 Reassurance in these cases would be based on negative NAAT-tests for M. genitalium, CT, NG +/- trichomonas; 7Azithromycin 500mgs stat then 
250mgs for 4 days; 8 If trichomonas NAAT-positive.  Metronidazole 400mgs  bid 5 days currently  recommended for treatment of possible bacterial vaginosis associated 
bacteria in European guideline[8] but benefit is unclear. 
Table 1 Exploring potential benefits associated with M. genitalium NAAT testing with or without antimicrobial resistance (AMR) testing in men presenting with symptoms 
of NGU compared to current standards of care. 
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